Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03151642 · ClinicalTrials.gov registry record
A Pilot Study OF Diffusion Weighted MRI TO Assess Esophageal Tumor Resonse TO Neoadjuvant Chemoradiation
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 11
- Enrollment target
NCT03151642 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 11 participants.
The verdict
NCT03151642 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The purpose of this research study will be to determine the sensitivity and specificity of dwMRI metrics to assess tumor response following neoadjuvant chemoradiation in esophageal cancer. This pilot study will generate the preliminary data needed for the design of a statistically-justified trial that would investigate dwMRI as an integral biomarker to stratify patients for escalated therapy to improve outcomes. We hope to develop dwMRI as a predictive clinical tool for a personalized treatment model that can identify patients who may be candidates for organ-preservation or treatment intensification to improve outcomes in esophageal cancer.
Interventions
- RADIATION Radiation Therapy
- PROCEDURE Surgery
- RADIATION Chemotherapy
- OTHER Blood Draws
- DEVICE MRI Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2021-04-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03151642
The ClinicalTrials.gov registry entry for NCT03151642 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Radiation Therapy is the first listed.
NCT03151642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03151642 about?
NCT03151642 is a clinical study titled "A Pilot Study OF Diffusion Weighted MRI TO Assess Esophageal Tumor Resonse TO Neoadjuvant Chemoradiation". The purpose of this research study will be to determine the sensitivity and specificity of dwMRI metrics to assess tumor response following neoadjuvant chemoradiation in esophageal cancer. This pilot study will generate the preliminary data needed for the design of a statistically-justified trial th...
What is the current status of trial NCT03151642?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2017-04-05. Estimated completion is 2021-04-23.
What interventions are being tested in trial NCT03151642?
The interventions under investigation include: Radiation Therapy (RADIATION), Surgery (PROCEDURE), Chemotherapy (RADIATION), Blood Draws (OTHER), MRI Imaging (DEVICE).
Who is sponsoring clinical trial NCT03151642?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.